Global Public Health | JNJ Innovation

Upholding the 130-year heritage of Johnson & Johnson, we are taking on the toughest challenges to advance healthcare for the world’s most vulnerable and underserved populations. The world has made signiﬁcant progress in providing healthcare, yet major gaps remain, and bolder, smarter approaches are needed to overcome the drastic inequity in access to care—now. As one of the world’s largest healthcare companies, we are driven to enable better health for more people in more places. Through a dedicated global public health (GPH) organization that includes research and development, global access strategies and programs, and local operations, we put the world’s most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved.

Focus Areas

We support innovation across the continuum of care to help develop the new technologies, treatments and vaccines needed to make progress against the world’s most life-threatening diseases. Recognizing we can’t do this alone, we seek to bring together public and private resources, invest in science both inside and outside of our walls and offer access to our R&D capabilities.

Click a circle below to see the conditions we are targeting.

Expanding access and uptake of existing regimens for multidrug- resistant TB (MDR-TB), developing simpliﬁed treatment regimens and novel molecular approaches; companion diagnostics.

TB

TB
Novel and simpliﬁed treatment tools, including new formulations, point-of-care diagnostics and others; innovative prevention tools and strategies, including vaccines, microbicides and other education/empowerment programs.

HIV

HIV
Dengue prevention and treatment; Chagas disease; Obstetric ﬁstula repair; preterm birth prevention; maternal/newborn survival; pandemic preparedness and emerging threat technologies and platforms (e.g., Ebola, Zika, etc.).

OTHERS

OTHERS
Johnson & Johnson, in partnership with WIPO Re:Search, is proud to make available its JumpstARter library to drug discovery researchers in order to identify and advance promising drug candidates to ﬁght neglected infectious diseases. The library includes a diverse collection of 80,000 high-quality drug-like small molecules and compound fragments created to “jump-start” drug discovery collaborations.

SHARING OUR MOLECULAR LIBRARIES

SHARING OUR MOLECULAR LIBRARIES

Collaboration Partners

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities.

Text left